Grace Therapeutics Inc. (ACST) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Grace Therapeutics Inc. (ACST:NASDAQ), powered by AI.

Current Price
$2.50
P/E Ratio
-1.4
Market Cap
19M
Sector
Healthcare
What is the Grace Therapeutics Inc. stock price forecast?

Grace Therapeutics Inc. is currently trading at $2.50. View real-time AI analysis on Alpha Lenz.

What is Grace Therapeutics Inc. insider trading activity?

View the latest insider trading data for Grace Therapeutics Inc. on Alpha Lenz.

What is Grace Therapeutics Inc.'s P/E ratio?

Grace Therapeutics Inc.'s P/E ratio is -1.4.

Grace Therapeutics Inc.

NASDAQ · ACST
$2.50-0.19(-7.06%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Grace Therapeutics Inc.'s future dividend policy...
Alpha Chat Insight

Grace Therapeutics Inc. trades at a P/E of -1.4 (undervalued) with modest ROE of -19.8%.

Ask for details

Company Overview

Grace Therapeutics Inc. is a biopharmaceutical company that specializes in the development of innovative therapies aimed at treating unmet medical needs, particularly in the field of rare and complex diseases. The company's primary focus is on optimizing drug delivery systems to enhance the efficacy and safety of existing therapeutics. Grace Therapeutics Inc. employs advanced technologies to reformulate existing molecules, thereby improving their bioavailability and therapeutic outcomes. Operating within the healthcare and life sciences sectors, Grace Therapeutics plays a transformative role by addressing critical gaps in current treatment options. It touches on various therapeutic areas, potentially offering novel solutions for conditions that have seen limited progress with standard approaches. By leveraging sophisticated drug reformulation techniques, the company seeks to improve patient adherence and outcomes, catering to both domestic and international markets. With a commitment to stringent research and development, Grace Therapeutics contributes significantly to the pharmaceutical industry's efforts to innovate and deliver more personalized and effective treatment solutions. Its strategic initiatives and collaborations position it as an influential player in the advancement of medical therapies, marking its significance in the healthcare market.

CEOMr. Prashant Kohli
SectorHealthcare
IndustryBiotechnology
0

Company Statistics

FY 2024

Profile

$18.59MMarket Cap
$0.00Revenue
0.00Shares Out
0Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-1.45P/E
0.30P/B
N/AEV/Sales
0.62EV/EBITDA
-1.50P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-16.86%ROA
-19.82%ROE
-14.92%ROIC

Financial Health

$23.00MCash & Cash Equivalents
$-11.45MNet Debt
18.72%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Grace Therapeutics Inc. (ticker: ACST) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). Market cap is $19M.

The current price is $2.5 with a P/E ratio of -1.45x and P/B of 0.3x.

ROE is -19.82%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Grace Therapeutics Inc. (ACST) Stock Forecast 2026 $2.50 — Price, Financials & Analyst Targets | Alpha Lenz